Literature DB >> 26801484

TLR4 preconditioning is associated with low success of OK-432 treatment for lymphatic malformations in children.

Marc Reismann1,2,3, Nader Ghaffarpour4,5, Ethel Luvall6, Adan Jirmo7, Josephine Radtke8, Gösta Claesson4,5, Tomas Wester4,5.   

Abstract

PURPOSE: We have recently shown that the relative TLR4 expression on monocytes of low responding pediatric patients after OK-432 treatment is significantly reduced after stimulation with lipopolysaccharide (LPS) compared with high responding children. The aim of this study was to perform further analysis to explain this observation.
METHODS: Monocytes from children with high (HR, n = 5) and low response (LR, n = 6) after previous OK-432 treatment were stimulated with LPS for 20 h and analyzed with fluorescence-activated cell sorting (mean fluorescence intensity, MFI; level of significance P ≤ 0.05).
RESULTS: Mean MFI after LPS stimulation was comparable in both groups (HR 1142 ± 652 units, LR 839 ± 427 units, P = 0.85). Significant changes after LPS stimulation are explained by higher pre-stimulation values in the LR group compared with the HR group (950 ± 718 vs. 477 ± 341, P = 0.25) with considerable differences of the mean expression changes after LPS stimulation (HR 665 ± 683 vs. LR -111 ± 605, P = 0.08).
CONCLUSION: The previously shown reduced TLR4 upregulation on monocytes after LPS stimulation in the LR group compared with the HR group can be primarily explained by TLR preconditioning. This observation implies the use of absolute values with definite thresholds.

Entities:  

Keywords:  Children; Lymphatic malformation; OK-432; Toll-like receptor

Mesh:

Substances:

Year:  2016        PMID: 26801484     DOI: 10.1007/s00383-016-3865-6

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  14 in total

1.  TLR4 and LPS hyporesponsiveness in humans.

Authors:  David A Schwartz
Journal:  Int J Hyg Environ Health       Date:  2002-04       Impact factor: 5.840

Review 2.  Percutaneous treatment of low flow vascular malformations.

Authors:  Patricia E Burrows; Keira P Mason
Journal:  J Vasc Interv Radiol       Date:  2004-05       Impact factor: 3.464

3.  Individual LPS responsiveness depends on the variation of toll-like receptor (TLR) expression level.

Authors:  Jun Jaekal; Edward Abraham; Tania Azam; Mihai G Netea; Charles A Dinarello; Jong-Seok Lim; Young Yang; Do-Young Yoon; Soo-Hyun Kim
Journal:  J Microbiol Biotechnol       Date:  2007-11       Impact factor: 2.351

4.  Pediatric lymphangiomas of the head and neck.

Authors:  L J Orvidas; J L Kasperbauer
Journal:  Ann Otol Rhinol Laryngol       Date:  2000-04       Impact factor: 1.547

5.  Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes.

Authors:  N Ghaffarpour; B Petrini; L A Svensson; K Boman; T Wester; G Claesson
Journal:  Acta Paediatr       Date:  2015-07-14       Impact factor: 2.299

6.  Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432.

Authors:  Masato Okamoto; Tetsuya Oshikawa; Tomoyuki Tano; Go Ohe; Sachiko Furuichi; Hidetomo Nishikawa; Sharif Uddin Ahmed; Sachiko Akashi; Kensuke Miyake; Osamu Takeuchi; Shizuo Akira; Yoichiro Moriya; Shuzo Matsubara; Yoshiki Ryoma; Motoo Saito; Mitsunobu Sato
Journal:  J Natl Cancer Inst       Date:  2003-02-19       Impact factor: 13.506

7.  Dynamic Toll-like receptor expression predicts outcome of sclerotherapy for lymphatic malformations with OK-432 in children.

Authors:  Marc Reismann; Nader Ghaffarpour; Ethel Luvall; Adan C Jirmo; Ola Winqvist; Josephine Radtke; Tomas Wester; Gösta Claesson
Journal:  J Surg Res       Date:  2013-10-02       Impact factor: 2.192

8.  A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism.

Authors:  Akihiro Fujino; Yoichiro Moriya; Yasuhide Morikawa; Ken Hoshino; Toshihiko Watanabe; Naoki Shimojima; Masaki Kitajima
Journal:  J Pediatr Surg       Date:  2003-12       Impact factor: 2.545

Review 9.  Congenital malformations of the cervicothoracic lymphatic system: embryology and pathogenesis.

Authors:  D P Zadvinskis; M T Benson; H H Kerr; A A Mancuso; A A Cacciarelli; B L Madrazo; M F Mafee; K Dalen
Journal:  Radiographics       Date:  1992-11       Impact factor: 5.333

Review 10.  Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature.

Authors:  Michelle T Poldervaart; Corstiaan C Breugem; Lucienne Speleman; Suzanne Pasmans
Journal:  J Craniofac Surg       Date:  2009-07       Impact factor: 1.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.